Adisord - instructions for use, dose, side effects, contraindications

Excipients: flavoring banana (essence banana) 0.6 mg, carbomer 971P 9 mg, citric acid anhydrous 0.75 mg, methyl parahydroxybenzoate 5 mg, sodium hydroxide 2 mg, sucrose 1000 mg, ethanol 96% 0.05 ml, water purified to 5 ml .

1 bottle contains:

Active substance: nifuroxazide 3.6 g;

Excipients: flavoring banana (essence banana) 0.0108 g, carbomer 971P 0.162 g, citric acid anhydrous 0.0135 g, methyl parahydroxybenzoate 0.09 g, sodium hydroxide 0.036 g, sucrose 18 g, ethanol 96% 0.9 ml, water purified to 90 ml .

Description:A homogeneous suspension of yellow color with the aroma of banana.

Pharmacotherapeutic group:Antimicrobial agent, nitrofuran

ATX: & nbsp

A.07.A.X.03 Nifuroxazide

Pharmacodynamics:

Nifuroxazide is an antimicrobial agent derived from nitrofuran. It blocks the activity of dehydrogenases and depresses the respiratory chains, the cycle of tricarboxylic acids and a number of other biochemical processes in the microbial cell. Destroys the membrane of a microbial cell, reduces the production of toxins by microorganisms. Highly active in relation to Campylobacter jejuni, Escherichia coli, Salmonella spp., Shigella spp.; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp. Weakly sensitive to nifuroxazide: Citrobacter spp., Enterobacter cloacae and Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp., Proteus mirabilis, Providencia spp., Pseudomonas spp. He disturbs the balance of the intestinal microflora. With acute bacterial diarrhea, eubiosis of the intestine is restored. When infected with enterotrophic viruses prevents the development of bacterial superinfection.

Pharmacokinetics:

After oral administration nifuroxazide practically not absorbed from the digestive tract and its antibacterial action exerts exclusively in the lumen of the intestine. Nifuroxazide is excreted by the intestine: 20% unchanged, and the rest of the nifuroxazide is chemically altered.

Indications:

Acute bacterial diarrhea, proceeding without deterioration of the general condition, fever, intoxication.

Contraindications:

Hypersensitivity to nifuroxazide, to derivatives of nitrofuran and other components of the drug;

Intolerance to fructose;

Syndrome of glucose-galactose malabsorption, insufficiency of sugar and isomaltase;

Pregnancy;

Newborn period (up to 1 month), prematurity.

Carefully:

Diseases of the liver, alcoholism, traumatic brain injury, brain disease, lactation,childhood.

Pregnancy and lactation:

In studies on animals, there was no teratogenic effect. However, as a precautionary measure, take nifuroxazide during pregnancy is not recommended. During the lactation period, it is possible to continue breastfeeding in the case of a short course of treatment with the drug. It is necessary to consult a doctor.

Dosing and Administration:

It is applied inside.

For dispensing a dosage spoon with a volume of 5 ml, having a calibration of 2.5 ml is used.

Before use, the suspension should be shaken well.

- Children from 1 to 6 months: 100 mg nifuroxazide (2.5 ml suspension) 2-3 times a day (the interval between doses is 8-12 hours).

- Children from 6 months to 3 years: 100 mg of nifuroxazide (2.5 ml of suspension) 3 times a day (the interval between meals is 8 hours).

- Children from 3 to 6 years: 200 mg nifuroxazide (5 ml suspension) 3 times a day (the interval between meals is 8 hours).

- Children from 6 to 18 years: 200 mg nifuroxazide (5 ml suspension) 3-4 times a day (the interval between doses is 6-8 hours).

- Adults: 200 mg of nifuroxazide (5 ml of suspension) 4 times a day (the interval between doses is 6 hours).

The duration of the course of treatment is 5-7 days, but not more than 7 days. If there is no improvement within the first 3 days, you should consult a doctor.Use the drug only according to the method of administration and the doses specified in the instructions. When please consult with your doctor before using the medication.

Side effects:

Allergic reactions (skin rash, hives, Quincke's edema, anaphylactic shock).

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

Symptoms of overdose are unknown. Treatment is symptomatic.

Interaction:It is not recommended simultaneous use with drugs that cause the development of disulfiram-like reactions, drugs that depress the central nervous system. If you are taking other medications (including over-the-counter drugs) before using Adisord®, consult your doctor.

Special instructions:

When treating diarrhea concomitantly with nifuroxazide therapy, rehydration therapy should be performed. Treatment of diarrhea in children under 3 years should be carried out under the supervision of a doctor.In the case of bacterial diarrhea with signs of systemic damage (worsening of the general condition, fever, symptoms of intoxication, or infection), you should consult your doctor to decide on the use of antibacterial agents of systemic action. If symptoms of hypersensitivity (dyspnea, rash, itching) appear, stop taking the drug. The use of alcohol during therapy with nifuroxazide is prohibited.

In connection with the content of methyl parahydroxybenzoate, the drug may cause allergic reactions (possibly delayed).

The drug Adisord® contains 1000 mg of sucrose in 5 ml. Respectively, the content of sucrose in a single dose of 2.5 ml of the suspension is 0.04165 XE (bread units), and in a single dose of 5 ml - 0.0833 XE.

The daily dose of sucrose is 0.0833 XE with the intake of 2.5 ml of suspension 2 times a day and 0.125 XE with the intake of 2.5 ml of suspension 3 times a day.

The daily dose of sucrose is 0.250 XE when taking 5 ml of suspension 3 times a day and 0.333 XE with 5 ml of suspension 4 times a day.

The content of 96% ethanol in the Adisord® suspension is 1%. The minimum single dose of the drug, corresponding to 100 mg of nifuroxazide (2.5 ml of suspension),contains 0,02 g of ethanol (in terms of absolute alcohol), and the maximum daily dose corresponding to 800 mg of nifuroxazide (5 ml of suspension 4 times a day) contains 0.16 g of ethanol (in terms of absolute alcohol).

Effect on the ability to drive transp. cf. and fur:The drug does not affect the ability to drive vehicles and mechanisms.

Form release / dosage:

Suspension for oral administration 200 mg / 5 ml.

Packaging:

For 90 ml in bottles of medical from dark container glass of the 1 st, 2 nd or 3 rd hydrolytic class, sealed with a screwed plastic cover providing control of the first opening.

A bottle with a measuring spoon together with the instruction for use is placed in a pack of cardboard.

Storage conditions:

At a temperature of no higher than 25 ° C in the manufacturer's packaging.

Keep inaccessible for children location.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-004822

Date of registration:24.04.2018

Expiration Date:24.04.2023

The owner of the registration certificate:Bakter, OOOBakter, OOO Russia

Manufacturer: & nbsp

AVZ S-P, LLC Russia

Information update date: & nbsp31.05.2018

Illustrated instructions

Instructions

Adisord® (Adisord®)